CURRICULUM VITAE

BIOGRAPHICAL

Name: Carmen Visus Birthdate: 03-13-1976

Home Address: 213 Emerson St.
Pittsburgh PA 15206 Birthplace: Zaragoza, Spain
Home Phone: 412-523-7064 Citizenship: Spain
E-Mail Address: mamenvisus@yahoo.es, cv4e7f2a@westpost.net
Business Address: University of Pittsburgh Cancer Institute
Hillman Cancer Center
Research Pavilion Suite 2.7
5117 Centre Avenue
Pittsburgh, PA 15213
Business Phone: 412-623-7877 Business Fax: 412-623-7768
EDUCATION and TRAINING
UNDERGRADUATE:
Dates Attended Name and Location Degree Received Major Subject of
Institution and Year
1998 University of Navarra B.S. Biology
GRADUATE:
Dates Attended Name and Location Degree Received Major Advisor
of Institution and Year and Discipline
2001 University of Zaragoza B.S. Biochemistry
2003 University of Zaragoza Ph.D. Immunology
POST-GRADUATE:
Dates Attended Name and Location of Name of Program Director
Institution and Discipline
2003-present Department of Pathology, University of Pittsburgh Albert Deleo

MEMBERSHIPS in PROFESSIONAL and SCIENTIFIC SOCIETIES

Organization Year
American Association of Cancer Research 2006-present
American Association of Immunologist 2009
TEACHING AND MENTORING EXPERIENCE
Teaching and mentoring experience at the Hillman Cancer Center with undergraduat
e, master and PhD students. Student from University of Pittsburgh and Carnegie M
ellon University are mentored and trained in Cancer Research and Immunology. Ins
truction to students to lymphocyte activation mechanisms, immunoregulation, cyto
kine biology, including immunosupression mechanisms by tumors, cancer stem cells
, murine cancer models, and clinical trials, including immunotherapy of cancer.
Trainees participate in these studies and are taught sound approaches for design
ing and conducting research.
Teaching course: EPIDEM 2272, Advanced Topics in Cancer Epidemiology and Prevent
ion, University of Pittsburgh.

HONORS AND AWARDS

Hirshberg Foundation Grant Award of $40,000 for Pancreatic Cancer Research; Prin
cipal Investigator, 2009-2010.
PUBLICATIONS
1.-Refereed articles
1. Visus C, Tsukishiro T, Ferris RL, Gooding W, Whiteside TL, DeLeo AB. Alterati
ons in the T-cell receptor variable* * gene?restricted profile of CD8+ T lymphoc
ytes in the peripheral circulation of patients with squamous cell carcinoma of t
he head and neck. Clin Cancer Res 2006; 12:2394-2403.
2. Ito D, Albers A, Zhao Y-X, Visus C, Appella E, Whiteside TL, DeLeo AB. The wi
ld type sequence p5325-35 induces HLA-DR7 and HLA-DR11-restricted CD4+ T helper
cells capable of enhancing the ex vivo expansion and function of anti-wild type
sequence p53264-272 peptide CD8+ T cells. J Immunol 2006; 177:6795-6803.
3. Ito D, Visus C, Hoffmann TK, Balz V, Bier H, Appella E, Whiteside TL, Ferris
RL, DeLeo AB. Immunological characterization of missense mutations occurring wit
hin cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinoma
s of the head and neck. Int J Cancer. 2007; 120:2618-24.
4. Mayordomo JI, Andres R, Isla MD, Murillo L, Cajal R, Yubero A, Blasco C, Lasi
erra P, Palomera L, Fuertes MA, Guemes A, Sousa R, Garcia-Prats MD, Escudero P,
Saenz A, Godino J, Marco I, Saez B, Visus C, Asin L, Valdivia G, Larrad L, Tres
A. Results of a pilot trial of immunotherapy with dendritic cells pulsed with au
tologous tumor lysates in patients with advance cancer. Tumori. 2007; 93(1):26-3
0.
5. Visus C, Andres R, Mayordomo JI, Martinez-Lorenzo MJ, Murillo, L, Saez-Gutier
rez B, Diestre C, Marcos I, Astier P, Godino J, Carapeto-Marquez de Prado FJ, La
rrad L, Tres A. Prognostic role of circulating melanoma cells detected by revers
e transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with m
elanoma. Melanoma Res. 2007 17(2):83-9.
6. Visus C, Ito D, Amoscato A, Maciejewska-Fraanczak M, Abdelsalem A, Dhir R, Sh
in DM, Donnenberg VS, Whiteside TL, De Leo AB. Identification of human aldehyde
dehydrogenase 1 family member A1 as a novel CD8+ T cell-defined tumor antigen in
squamous cell carcinoma of the head and neck. Cancer Res 2007; 67:10538-45.
7. AndreR, Mayordomo JI, Visus C, Isla D, Escudero P, Aguirre E, Lastra R, Elose
gui L, Saenz A, Godino J, Marcos I, Ortega E, Lambea J, Ruiz-Echarri M, Millastr
e E, Giner A, Carapeto FJ, Tres A. Prognostic significance and diagnostic value
of protein S-100 and tyrosinase in patients with malignant melanoma. Am J Clin
Oncol 2008; 31(4):335-9.
8. Alvarez-Busto I, Albers A, Visus C, Mayordomo JI, Sanz J, Burillo MA, Guemes
A, Garcia-Prats MD, Moros M, DeLeo A & Tres A. Deteccion de linfocitos T citotox
icos contra los epitopos 264-272 y 149-157 de la proteina p53 en sangre periferi
ca de pacientes con cancer de mama. Med Clin 2008; 131(18): 685-8.
9. Albers AE, Schaefer C, Visus C, Gooding W, DeLeo AB and Whiteside TL. Spontan
eous Apoptosis of Epitope-Specific Tetramer+ CD8+ T Lymphocytes in the Periphera
l Circulation of Patients with Head and Neck Cancer. Head and Neck 2009, Jun, 31
(6) 773-81.
10. Hendrickson RC, Cicinnati VR, Albers A, Dworacki G, Gambotto A, Pagliano O,
T?T, Mayordomo JI, Visus C, Appella E, Shabanowitz J, Hunt DF, Deleo AB. Identif
ication of a 17beta-hydroxysteroid dehydrogenase type 12 pseudogene as the sourc
e of a highly restricted BALB/c Meth A tumor rejection peptide. Cancer Immunol I
mmunother. 2009 Jun 27.
11. Wieckowski EU, Visus C, Szajnik M, Szczepanski MJ, Storkus WJ, Whiteside TL.
 Tumor-derived microvesicles promote regulatory T cell expansion and induce apop
tosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol. 2009 Sep 15;183
(6):3720-30.

2. Reviews, invited published papers, proceedings of conferences and symposia, m

onographs, books and book chapters.
1. Murillo L, Vis? Mayordomo JI, Marti(R)z-Lorenzo MJ, Isla MD, Garci*Prats MD
, Ageitos A, Sousa R, Razola A, Prats E, Banzo J, Deleo A, Larrad L, Tres A. D
endritic cell culture for immunotherapy in melanoma patients. CSEI 2002.
2. Diestre C, Alava MA, Anel A, Vis? Sa-Gutierrez B, Lasierra P, Larrad L, Marti
(R)z-Lorenzo MJ. cDNA immunitation to obtain anti-FasL policlonal antibodies. CS
EI 2002.
3. Marti(R)z-Lorenzo MJ, Anel A, Sa-Gutierrez B, Vis? Diestre C, Lasierra P, Lar
rad L. Fas, FasL and Apo2L study in T lymphocytes from synovial liquid in rheuma
toid arthritis patients. CSEI 2002.
4. Sa Gutierrez B., Marti(R)z-Lorenzo M.J., Diestre C., Vis? Lasierra P., Larrad
L. Toxicity study of zidovudin, indinavir, neflavir and saquinavir in lymphocyt
es from HIV patients and normal controls. AIDS Spanish Association 2002.
5. Marti(R)z-Lorenzo M.J., Sa-Gutierrez B., Vis?, Diestre C., Lasierra P., Larra
d L. Analysis of expression of Fas, FasL and Apo2L in lymphocytes from HIV patie
nts and sensitivity to apoptosis. AIDS Spanish Association 2002.
6. Vis?, Marti(R)z-Lorenzo M.J., Murillo L., Mayordomo J.I., AndreR., Filipovich
E., Diestre C., Sa-Gutieez B., Larrad L. & Tres A. Evaluation of the prognostic
role of circulating melanoma cells detected by reverse transcriptase polimerase
chain reaction for tyrosinase RNA. ASCO (American Society of Clinical Oncology)
, Oral communication, Chicago, June 2003.
7. Visus C, Dhir R, Whiteside TL, and DeLeo AB, Identification of 17*-hydroxyste
roid dehydrogenase type 12 (HSD17B12) as a shared tumor antigen of squamous cell
carcinomas of the head and neck (SCCHN) University of Pittsburgh Cancer Instit
ute, 2006.
8. Ito D, Visus C, Amoscato A, Whiteside TL, DeLeo A. Aldehyde dehydrogenase 1 f
amily, member A1 (ALDH1A1): A novel tumor antigen of human squamous cell carcino
ma of head and neck (SCCHN). University of Pittsburgh Cancer Institute, 2006.
9. Herrin VE, Achtar MS, Steinberg SM, Whiteside TL, Wieckowski E, Visus C, Berz
ofsky JA, Khleif SN. A randomized phase II p53 vaccine trial comparing subcutane
ous direct administration with intravenous peptide-pulsed dendritic cells in hig
h risk ovarian cancer patients. Chicago, 2007 ASCO.
10. Visus C, Ito D, Amoscato A, Dhir R, Maciejewska-Franczak M, Abdelsalam A, Wh
iteside TL, DeLeo A. Aldehyde dehydrogenase 1 family, member A1 (ALDH1A1): A no
vel tumor antigen of human squamous cell carcinoma of head and neck (SCCHN). LA,
2007 AACR.
11. Gangopadhyay NN, Visus C, Shen H, Luketich JD, Shuchert MJ. Clonally selecte
d hematopoietic stem cells as a tool for gene therapy. 2007 FARF.
12. Visus C. et al. Targeting ALDH1A1 for Immunotherapy of Cancer Stem Cells. Am
erican Association of Immunologist, Seattle, 2009.

? LIST OF CURRENT RESEARCH INTERESTS:

Development of p53-based cancer vaccines: Identification and characterization of
HLA class I and II-restricted wild type sequence and mutant p53 peptides.
Clinical-based studies related to p53 immune responses in patients with head and
neck, breast, ovarian and lung carcinomas.
Identification and characterization of T cell-defined peptides derived from alde
hyde dehydrogenase 1 (ALDH1A1) and 17 * steroid dehydrogenase type 12 (HSD17B12)
expressed on human squamous cell carcinomas of the head and neck.
Alterations in expression and function of glucosidase I and II in human squamous
cell carcinomas of the head and neck and HLA class I expression.
Immunotherapy targeting ALDH1A1 for Cancer Stem Cells.